Natera Signatera PMDA Approval Bladder Cancer
Analysis based on 6 articles · First reported Sep 22, 2026 · Last updated Sep 22, 2026
The approval expands Natera's addressable market in Japan for its Signatera molecular residual disease test, a positive long-term revenue driver though commercial launch is not expected until the first half of 2027. Near-term market reaction was muted to slightly negative, with Natera shares down 1.47 percent pre-market, suggesting the approval was largely anticipated by investors.
Natera announced that its Signatera test received regulatory approval from Japan's Japan — Pharmaceuticals and Medical Devices Agency as a companion diagnostic in muscle-invasive bladder cancer. The approval supports the use of Signatera to guide adjuvant atezolizumab treatment decisions in patients with MIBC. Natera expects to commercially launch Signatera for MIBC in Japan in the first half of 2027, following the PMDA approval of atezolizumab in MIBC. The regulatory approval was supported by data from IMvigor011, a randomized, double-blind phase III clinical trial that evaluated Signatera-guided adjuvant atezolizumab in patients with MIBC, and included more than 20 participating sites in Japan. This marks Signatera's second PMDA authorization in Japan, after receiving approval in colorectal cancer in June 2026. It follows the United States — Food and Drug Administration approval of Signatera as a companion diagnostic for adjuvant atezolizumab in MIBC, as well as a recently published Category 1 recommendation for MRD-guided adjuvant atezolizumab in the National Comprehensive Cancer Network Clinical Practice Guidelines for Bladder Cancer. Bladder cancer affects more than 34,000 people in Japan each year, with approximately 20-25 percent of newly diagnosed cases classified as muscle-invasive. Natera shares traded down 1.47 percent to $365.20 in pre-market trading on Nasdaq.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard